Navigation Links
High and Super-High Potency Topical Corticosteroids Will Remain Decision Resources' Clinical Gold Standard Through 2017 for the Treatment of Atopic Dermatitis

A Once-Daily Topical Agent With a Novel Mechanism of Action and Efficacy Advantages Over Elidel Would Earn Higher Patient Share in the U.S. Than in Europe, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that high and super-high potency topical corticosteroids (TCSs) will remain Decision Resources' proprietary clinical gold standard through 2017 for the treatment of atopic dermatitis. While some therapies in development for the disease hold promise, most have efficacy, safety and tolerability and/or delivery issues.

"Although efficacious drugs like high and super-high potency TCSs are available, they are predominantly used to treat adult patients with severe atopic dermatitis," stated Kyle Crowell, analyst at Decision Resources. "For pediatric and adult patients with less severe atopic dermatitis, physicians prefer to prescribe drugs with superior safety profiles. Improvements in safety and tolerability would provide a competitive advantage for an emerging atopic dermatitis drug."

The new report entitled Atopic Dermatitis: A Market with Well-Established First-Line Agents Still Needs a Safe Maintenance Therapy also finds that a once-daily topical agent with a novel mechanism of action and efficacy advantages over Novartis' Elidel would earn 35 percent patient share in the atopic dermatitis drug market, according to surveyed U.S. dermatologists. On the other hand, in Europe, such an agent would earn a 25 percent patient share, according to surveyed European dermatologists.

About the Report

Atopic Dermatitis: A Market with Well-Established First-Line Agents Still Needs a Safe Maintenance Therapy is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Natalia Morales                        Elizabeth Marshall
    Decision Resources                     Decision Resources, Inc.
    781-296-2691                           781-296-2563      

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. SAFC Pharma(TM) Commits to Major Expansion of High Potency API Production at Madison Site
2. Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1%
3. Bariatric Advantage Announces New Higher-Potency Iron Supplement for Weight Loss Surgery Patients
4. Novel molecules developed at UB can boost vaccine potency
5. Nordic Naturals Professional Exclusive Division Redefines High Potency Omega-3 Supplementation With New Elite Line!
6. Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis
7. Ready-To-Use Products Spur the European Tissue Sealants and Topical Hemostats Markets, Says Frost & Sullivan
8. New topical approach to treating nail fungus circumvents problems with current therapy
9. Topical treatment for cold sores achieves efficacy of oral drugs; represents paradigm shift
10. Topical oral syrup prevents early childhood caries
11. Nuvo licenses topical pain product from Paladin
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the Radiology ... Building Better Radiology Marketing Programs meeting will showcase some of the best ... at Caesars Palace in Las Vegas with a pre-conference session on a collaborative ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in mind challenges faced ... and wellness consultation, has collaborated with a leading web-based marketplace for extra-curricular activities ... by parents and bring advice from parenting experts within their reach. As a ...
(Date:11/27/2015)... ... 27, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces ... This is one of Joplin's most famous and beautiful concert posters. The concert was ... in Ann Arbor. The According to Hawley, "It is hard to believe that Joplin's ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and ... diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians can ... from their electronic medical record (EMR) without the need for redundant patient entry ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is ... 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! , “What an ... every day excited to rebuild lives and it’s an honor to have served all ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 3D bioprinting market ... according to a new report by Grand View Research Inc. ... (CKD) which demands kidney transplantation is expected to boost the ... substitute for organ transplantation. --> 3D bioprinting market ... according to a new report by Grand View Research Inc. ...
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the German ...
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
Breaking Medicine Technology: